Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease

• Published in: Intestinal research 2024, 22(1), , pp.15-43
• Main Authors: Pandey, Himani, Jain, Dheeraj, Tang, Daryl W. T., Wong, Sunny H., Lal, Devi
• Format: Article
• Language: English
• Subjects: crohn disease; fecal microbiota transplantation; inflammatory bowel disease; microbiota; Review; ulcerative colitis; 내과학
• ISSN: 1598-9100; 2288-1956
• DOI: 10.5217/ir.2023.00080

Inflammatory bowel disease (IBD) is a multifactorial disease, which is thought to be an interplay between genetic, environment, microbiota, and immune-mediated factors. Dysbiosis in the gut microbial composition, caused by antibiotics and diet, is closely related to the initiation and progression of IBD. Differences in gut microbiota composition between IBD patients and healthy individuals have been found, with reduced biodiversity of commensal microbes and colonization of opportunistic microbes in IBD patients. Gut microbiota can, therefore, potentially be used for diagnosing and prognosticating IBD, and predicting its treatment response. Currently, there are no curative therapies for IBD. Microbiota-based interventions, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, have been recognized as promising therapeutic strategies. Clinical studies and studies done in animal models have provided sufficient evidence that microbiota-based interventions may improve inflammation, the remission rate, and microscopic aspects of IBD. Further studies are required to better understand the mechanisms of action of such interventions. This will help in enhancing their effectiveness and developing personalized therapies. The present review summarizes the relationship between gut microbiota and IBD immunopathogenesis. It also discusses the use of gut microbiota as a noninvasive biomarker and potential therapeutic option.